Polyene Phosphatidylcholine

PreclinicalSmall molecule

Polyene Phosphatidylcholine is one of 18 small molecule programs targeting Hyperbilirubinemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperbilirubinemiaActive, not recruiting

HyperbilirubinemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Hyperbilirubinemia

#DrugCompanyPhaseTrials

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Approved

3 2

Immunoglobulin

Sanofi

Approved

1 3

Verazinc

FFakultas Kedokteran Universitas Indonesia

Phase 2

2 4

Zinc Gluconate

Johnson & Johnson

Phase 2

1 5

Gemzar

Johnson & Johnson

Phase 1

1 6

Abraxane

Bristol-Myers Squibb

Phase 1

1 7

Medrol

Pfizer

Preclinical

1 8

Tricor

JJagotec

Preclinical

2 9

Stannsoporfin

IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

Phase 2

1 10

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Not yet recruiting

Hematological Diseases

NCT07476885

Q3 2027

N/ARecruiting

Hyperbilirubinemia

NCT06922669

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

Completed·AAMIpharm Co., Ltd.·Phase 3·NCT06256445·252 enrolled

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat

Completed·AAMIpharm Co., Ltd.·Phase 2·NCT03982225·143 enrolled

Hyperbilirubinemia1 trial

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06922669·232 enrolled

Hematological Diseases1 trial

A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China··NCT07476885·1,000 enrolled

Double-blind1 trial

The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Completed·DDrug Induced Liver Disease Study Group·Phase 2·NCT02944552·244 enrolled

Unspecified2 trials

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

Completed·AAMIpharm Co., Ltd.·Phase 1·NCT05476094·26 enrolled

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Completed·AAMIpharm Co., Ltd.·Phase 2·NCT05266729·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Polyene Phosphatidylcholine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polyene Phosphatidylcholine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polyene Phosphatidylcholine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AMIpharm Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAMIpharm Co., Ltd.

Polyene Phosphatidylcholine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Efficacy and Safety2 trials

Hyperbilirubinemia1 trial

Hematological Diseases1 trial

Double-blind1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News